TELA Bio Inc
NASDAQ:TELA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TELA Bio Inc
Net Income (Common)
TELA Bio Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TELA Bio Inc
NASDAQ:TELA
|
Net Income (Common)
-$38.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Net Income (Common)
$175.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Net Income (Common)
$732k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-62%
|
CAGR 10-Years
-34%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Net Income (Common)
$410.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
11%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Net Income (Common)
$233.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Net Income (Common)
$128.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
TELA Bio Inc
Glance View
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
See Also
What is TELA Bio Inc's Net Income (Common)?
Net Income (Common)
-38.8m
USD
Based on the financial report for Dec 31, 2025, TELA Bio Inc's Net Income (Common) amounts to -38.8m USD.
What is TELA Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-6%
Over the last year, the Net Income (Common) growth was -3%. The average annual Net Income (Common) growth rates for TELA Bio Inc have been 4% over the past three years , -6% over the past five years .
